<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739280</url>
  </required_header>
  <id_info>
    <org_study_id>1000-1</org_study_id>
    <nct_id>NCT04739280</nct_id>
  </id_info>
  <brief_title>Women's Assessed Cardiovascular Evaluation With MCG</brief_title>
  <acronym>WACE-MCG</acronym>
  <official_title>Women's Assessed Cardiovascular Evaluation With MCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetesis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genetesis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25,&#xD;
      accounting for 1 of every 3 female deaths. Research has shown that while hypertension in&#xD;
      women is less controlled, they are also less likely to be identified with ischemic heart&#xD;
      disease and when diagnosed treated less aggressively than men. Moreover, women who are&#xD;
      diagnosed with breast cancer have an increased risk for cardiovascular disease. The Women's&#xD;
      Assessed Cardiovascular Evaluation with MCG (WACE-MCG) study is designed to collect&#xD;
      CardioFlux scans on a select group of female volunteers who are Ms. Medicine patients.&#xD;
      CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of&#xD;
      the heart to detect various forms of heart disease. There will be a 12-month duration of the&#xD;
      study where we propose to collect screening data from approximately 200 volunteers who&#xD;
      present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be&#xD;
      contacted at intervals over a 1-year period for follow-up data and may choose whether or not&#xD;
      they would like to provide follow-up data or participate in another scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy Statistics</measure>
    <time_frame>6 Months</time_frame>
    <description>analyzing the accuracy of CardioFlux</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity Statistics</measure>
    <time_frame>6 months</time_frame>
    <description>analyzing the specificity of CardioFlux</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemia</condition>
  <condition>Cardiac Disease</condition>
  <condition>Risk Factor, Cardiovascular</condition>
  <arm_group>
    <arm_group_label>Single center registry for WACE</arm_group_label>
    <description>We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not an intervention</intervention_name>
    <description>Not an intervention</description>
    <arm_group_label>Single center registry for WACE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The following describes the targeted population population&#xD;
&#xD;
        ≥ 18 years of age at the time of enrollment. Female Patients deemed at risk for&#xD;
        cardiovascular disease (breast cancer survivors, patients referred to cardiologists, prior&#xD;
        COVID-19 patients, etc.)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ≥ 18 years of age at the time of enrollment. Female Patients deemed at risk for&#xD;
        cardiovascular disease (breast cancer survivors, patients referred to cardiologists, prior&#xD;
        COVID-19 patients, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        &lt; 18 years of age Patients unable to fit into device Non-ambulatory patients Positive&#xD;
        response on CardioFlux Pre-Screening Form Patients with claustrophobia or unable to lie&#xD;
        supine for 5 minutes Pregnant women Poor candidate for follow-up (e.g. no access to phone)&#xD;
        Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must identify as Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Senagore, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genetesis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Senagore, M.D.</last_name>
    <phone>513-715-5045</phone>
    <email>anthony@genetesis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Legreaux, M.S.</last_name>
    <phone>513-715-5045</phone>
    <email>sam.legreaux@genetesis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genetesis Facility</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Legreaux, M.S.</last_name>
      <phone>513-715-5045</phone>
      <email>sam.legreaux@genetesis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://my.clevelandclinic.org/health/diseases/17645-women--cardiovascular-disease</url>
    <description>Women &amp; Cardiovascular Disease</description>
  </link>
  <reference>
    <citation>Duda-Pyszny D, Trzeciak P, Gąsior M. Coronary artery disease in women. Kardiochir Torakochirurgia Pol. 2018 Mar;15(1):44-48. doi: 10.5114/kitp.2018.74675. Epub 2018 Mar 28. Review.</citation>
    <PMID>29681961</PMID>
  </reference>
  <reference>
    <citation>Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular Disease in Women: Clinical Perspectives. Circ Res. 2016 Apr 15;118(8):1273-93. doi: 10.1161/CIRCRESAHA.116.307547. Review.</citation>
    <PMID>27081110</PMID>
  </reference>
  <reference>
    <citation>Merz CN, Kelsey SF, Pepine CJ, Reichek N, Reis SE, Rogers WJ, Sharaf BL, Sopko G. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol. 1999 May;33(6):1453-61.</citation>
    <PMID>10334408</PMID>
  </reference>
  <reference>
    <citation>Baldassarre LA, Raman SV, Min JK, Mieres JH, Gulati M, Wenger NK, Marwick TH, Bucciarelli-Ducci C, Bairey Merz CN, Itchhaporia D, Ferdinand KC, Pepine CJ, Walsh MN, Narula J, Shaw LJ; American College of Cardiology's Cardiovascular Disease in Women Committee. Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease. JACC Cardiovasc Imaging. 2016 Apr;9(4):421-35. doi: 10.1016/j.jcmg.2016.01.004. Review.</citation>
    <PMID>27056162</PMID>
  </reference>
  <reference>
    <citation>Barish R, Lynce F, Unger K, Barac A. Management of Cardiovascular Disease in Women With Breast Cancer. Circulation. 2019 Feb 19;139(8):1110-1120. doi: 10.1161/CIRCULATIONAHA.118.039371. Review.</citation>
    <PMID>30779651</PMID>
  </reference>
  <reference>
    <citation>Chaikovsky I, Hailer B, Sosnytskyy V, Lutay M, Mjasnikov G, Kazmirchuk A, Bydnyk M, Lomakovskyy A, Sosnytskaja T. Predictive value of the complex magnetocardiographic index in patients with intermediate pretest probability of chronic coronary artery disease: results of a two-center study. Coron Artery Dis. 2014 Sep;25(6):474-84. doi: 10.1097/MCA.0000000000000107.</citation>
    <PMID>24667125</PMID>
  </reference>
  <reference>
    <citation>Goernig M, Liehr M, Tute C, Schlosser M, Haueisen J, Figulla HR, Leder U. Magnetocardiography based spatiotemporal correlation analysis is superior to conventional ECG analysis for identifying myocardial injury. Ann Biomed Eng. 2009 Jan;37(1):107-11. doi: 10.1007/s10439-008-9598-5. Epub 2008 Nov 18.</citation>
    <PMID>19015988</PMID>
  </reference>
  <reference>
    <citation>Hailer B, Chaikovsky I, Auth-Eisernitz S, Schäfer H, Van Leeuwen P. The value of magnetocardiography in patients with and without relevant stenoses of the coronary arteries using an unshielded system. Pacing Clin Electrophysiol. 2005 Jan;28(1):8-16.</citation>
    <PMID>15660796</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Magnetic Field Map</keyword>
  <keyword>CardioFLux</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Magnetocardiography</keyword>
  <keyword>MCG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

